Literature DB >> 26352427

Review of treatment options for oligometastatic non-small cell lung cancer.

Michael R Folkert1, Robert Timmerman1.   

Abstract

Our understanding of metastatic disease is constantly evolving. Although outcomes for patients with stage IV non-small cell lung cancer (NSCLC) are poor, aggressive/radical local intervention may be effective in a subset of patients with limited or "oligometastatic" disease. Here we review and compare the range of available treatment options that are specific to oligometastatic NSCLC, and discuss potential directions of future clinical research.

Entities:  

Mesh：

Year:  2015        PMID： 26352427

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


  3 in total

Review 1.  Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.

Authors:  Meghan Campo; Hani Al-Halabi; Melin Khandekar; Alice T Shaw; Lecia V Sequist; Henning Willers
Journal:  Oncologist       Date:  2016-06-27

2.  Successful treatment of hepatic oligometastases with stereotactic ablative radiotherapy and radiofrequency ablation in an anaplastic lymphoma kinase fusion-positive lung cancer patient.

Authors:  Britta Weber; Mitchell Liu; Paul Sobkin; Stephan W Morris; David Hout; Nicholas van der Westhuizen; R Petter Tonseth; David L Saltman
Journal:  J Med Radiat Sci       Date:  2015-10-03

3.  Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients.

Authors:  Karmen Stanic; Nina Turnsek; Martina Vrankar
Journal:  Radiol Oncol       Date:  2019-11-20       Impact factor: 2.991
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.